Medical/Pharmaceuticals

Rayence Launches 'SHINE,' a Next-Generation X-ray Image Processing Technology for Low Dose Imaging

- Development of next-generation denoising image processing technology 'SHINE' completed; full-scale commercialization now underway - Development of 'Dynamic SHINE,' optimized for real-time C-arm fluoroscopy, also completed - SHINE is expected to help global X-ray equipment manufacturers acceler...

2026-07-14 21:00 3400

Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer

HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the pe...

2026-07-14 16:18 3610

Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities

SAN DIEGO, July 13, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion topics were about early-stage innovation assets, late-stag...

2026-07-14 00:00 4376

HKEY-AI-NAM-Bridge™ 1.0: HKeyBio Connects AI, NAMs and In Vivo Evidence

HKEY-AI-NAM-Bridge™ 1.0 connects AI predictions, new approach methodologies and in vivo evidence for more targeted preclinical study design BOSTON and SUZHOU, China, July 13, 2026 /PRNewswire/ -- HKeyBio has establishedHKEY-AI-NAM-Bridge™ 1.0, its AI and New Approach Methodologies (NAMs) In Vivo...

2026-07-13 21:16 3685

IMG Opens Applications for 2026 Fall Semester 'Student Journey Scholarship'

INDIANAPOLIS, July 13, 2026 /PRNewswire/ -- IMG (International Medical Group) is now accepting applications for itsStudent Journey Scholarship

2026-07-13 21:00 2927

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

* Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies.   * The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical ...

2026-07-13 20:30 2314

Delonix Bioworks Announces First Participant Dosed in Phase 1 Clinical Trial of Next-Generation MenB OMV Vaccine DX-104 in China

SHANGHAI, July 13, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical trial of DX-104 in China. DX-104 is an innovative Group B menin...

2026-07-13 20:00 3277

Advancing Low-Carbon Manufacturing and Global Sustainability Commitments

Report highlights clean energy, innovation and ESG recognition ZIBO, China, July 13, 2026 /PRNewswire/ -- INTCO Medical  ("the Company"), a leading global manufacturer of disposable gloves, has released its 2025 Environmental, Social and Governance (ESG) Report, ou...

2026-07-13 17:19 4507

Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline

NANJING, China, July 13, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that six of its latest research studies have been accepted for presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congres...

2026-07-13 16:56 4179

Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation

* Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment * Granted claims are not expressly limited to specific antibody CDRs or amino acid sequences, but are defined by func...

2026-07-13 16:53 2723

KLN Signs MOU with Advantech and YDCare to Support Digital Transformation of Hong Kong's Healthcare System

HONG KONG, July 13, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announced that its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), has signed a tripartite Memorandum of Understanding (MOU) with Advantech Co., Ltd. ('Advantech'; Stock Code 2395.TW), a g...

2026-07-13 12:19 3271

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2026 LIFESTYLE PROGRAM IMPROVES BRAIN HEALTH AMONG OLDER ADULTS AT RISK FOR DEMENTIA ACROSS LATIN AMERICA

- LatAm-FINGERS Study Findings Confirm and Expand U.S. POINTER Trial Results - - Show Structured Dementia Risk Reduction Strategies Adaptable Across Cultures - Key Takeaways * The LatAm-FINGERS study shows lifestyle interventions adapted across Latin American cultures, health systems and commu...

2026-07-13 12:01 2906

Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB

SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-07-13 12:00 3694

AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities

* 873 employees volunteered more than 3,600 hours across 7 Asian markets to support local communities. * Employees partnered with 21 community organizations, positively impacting more than 4,300 people through initiatives focused on patient support, inclusion, education and environmental su...

2026-07-13 10:00 2801

Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases

SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI),and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical ...

2026-07-13 08:30 3814

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2026

FORMER ELITE SOCCER PLAYERS SHOW EVIDENCE OF BRAIN HEALTH CHANGES IN MID-LIFE Key Takeaways * New research provides insights into brain health among former elite professional soccer players during midlife. * Former players reported high levels of depression, anxiety, and subjective difficult...

2026-07-12 12:01 3635

Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC

NANJING, China, July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of adva...

2026-07-10 16:53 5113

Professor Gang Shen's Orthodontic Team Publishes Third Consecutive Paper in the Journal of Aligner Orthodontics

SHANGHAI, July 8, 2026 /PRNewswire/ -- Professor Gang Shen, Chief GS R&D Scientist of Smartee Denti-Technology and Chief Orthodontist at Taikang Dental, together with his orthodontic team, has published a new researcharticle titled " Pathological Mandibular Retrusion: Causality and Orthodontic Int...

2026-07-09 17:55 4270

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective...

2026-07-09 17:28 4582

WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PL...

2026-07-09 15:31 4524
1 ... 27282930313233 ... 643